4.6 Article

Biomarkers of Kidney Tubule Disease and Risk of End-Stage Kidney Disease in Persons With Diabetes and CKD

Journal

KIDNEY INTERNATIONAL REPORTS
Volume 7, Issue 7, Pages 1514-1523

Publisher

ELSEVIER SCIENCE INC
DOI: 10.1016/j.ekir.2022.03.033

Keywords

biomarkers; chronic kidney disease; diabetes mellitus; end-stage kidney disease

Funding

  1. Baxter International
  2. Bayer Healthcare Pharmaceuticals, Inc
  3. Cricket Health
  4. CKD Bio- markers Consortium - National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health [U01DK102730]
  5. National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health [U01DK102730]
  6. National Institute of Neurological Disorders and Stroke [K24DK110427]
  7. National Institute on Aging, National Institutes of Health, Department of Health and Human Services
  8. [F32DK126381]

Ask authors/readers for more resources

For individuals with diabetes and CKD, urine biomarkers of kidney health may provide better understanding of disease progression. This study found that higher levels of urine KIM-1, α-1-microglobulin, and MCP-1 were independently associated with incident ESKD in adults with diabetes and eGFR < 60 ml/min per 1.73 m(2).
Introduction: Tubulointerstitial damage in diabetes and chronic kidney disease (CKD) is poorly captured by estimated glomerular filtration rate (eGFR) and albuminuria. Urine biomarkers of kidney health may better elucidate disease progression in persons with diabetes and CKD. Methods: Per case-cohort design, we randomly selected a subcohort of 560 study participants of the REasons for Geographic And Racial Differences in Stroke (REGARDS) study from 1092 adults with diabetes and baseline eGFR < 60 ml/min per 1.73 m(2) and registered a total of 161 end-stage kidney disease (ESKD) cases (n = 93 from the subcohort; n = 68 from outside the subcohort) during 4.3 +/- 2.7 years mean follow-up. We measured urine biomarkers of kidney tubule injury (kidney injury molecule-1 [KIM-1]), inflammation and fibrosis (monocyte chemoattractant protein-1 [MCP-1]), repair (chitinase-3-like protein 1 [YKL-40]), and tubule function, including reabsorption (alpha-1-microglobulin [alpha 1m]) and synthetic capacity (epidermal growth factor [EGF] and uromodulin [UMOD]). Weighted Cox regression models estimated ESKD risk adjusting for demographics, ESKD risk factors, and baseline eGFR and urine albumin. Least absolute shrinkage and selection operator (LASSO) regression identified a subset of biomarkers most strongly associated with ESKD. Results: At baseline, subcohort participants had mean age of 70 +/- 9 years, mean eGFR of 40 +/- 13 ml/min per 1.73 m(2), and median urine albumin-to-creatinine ratio of 33 (interquartile range 10-213) mg/g. Adjusting for baseline eGFR and albuminuria, each 2-fold higher urine KIM-1 (hazard ratio = 1.43 [95% CI: 1.17-1.75]), alpha 1m (hazard ratio = 1.47 [1.19-1.82]), and MCP-1 (hazard ratio = 1.27 [1.06-1.53]) were independently associated with ESKD. LASSO retained KIM-1 and a1m for associations with ESKD. Conclusion: Among adults with diabetes and eGFR < 60 ml/min per 1.73 m(2), higher urine KIM-1, alpha 1m, and MCP-1 are independently associated with incident ESKD, providing insight into kidney disease progression in persons with diabetes and CKD.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available